BioProcess Technology Consultants (BPTC), a leading US biopharmaceutical Chemistry, Manufacturing, and Controls (CMC) consulting company, announced the signing of a consulting agreement with Angel Biotechnology Plc (Angel), Edinburgh, Scotland, to provide business development and marketing assistance in North America for Angel’s cGMP cell therapy manufacturing capabilities.

BPTC will help reinforce Angel’s marketing strategy and introduce the company to new customers requiring its advanced cell therapy development and cGMP manufacturing services. The agreement is structured to operate as a partnership that will facilitate Angel’s procurement of both short and longer term contracts targeting primarily the expanded capacity at the company’s Cramlington facility.

“We are pleased to be working with Angel to offer business development assistance as well as technical and manufacturing support to the growing number of US cell therapy companies,” said Howard L Levine, PhD, president and principal consultant, BPTC. “The need to manufacture these products in a fully cGMP compliant facility to ensure reliable and reproducible treatments for patients is essential as they progress through rigorous clinical development and eventual commercialization. BPTC recognizes the need for experienced contract manufacturers to assist companies in meeting the unique manufacturing, quality, and regulatory challenges of these products. As a leader in providing these services to cell therapy companies, Angel is an ideal partner to assist North American companies developing cell therapy products. With our proprietary database of biopharmaceutical products in development and our network of North American industry contacts, we are uniquely positioned to assist Angel in identifying new clients for its cell therapy manufacturing services,” added Dr Levine.

“We look forward to harnessing BPTC’s wealth of industry experience and expertise to enhance our marketing strategy for the North American cell therapy manufacturing market,” said Gordon Sherriff, chief operating officer of Angel Biotechnology Holdings Plc. “Having such a talented and highly regarded biotechnology consulting company as our partner in this key market is a significant step forward for Angel. BPTC’s vast network of industry connections, especially in the North American biotech market, will provide key contacts with potential new clients to accelerate the growth of angel’s pipeline of cell therapy contracts.”

Angel Biotechnology Holdings plc is a full service contract bio-manufacturing partner to biotechnology and pharmaceutical companies worldwide and it also specializes in advanced biologics including biopharmaceutical proteins and cell therapies, such as cellular vaccines and stem cells.